KLK3 and cancer: Traditional disease monitoring approaches, including circulating prostate specific antigen (PSA) levels or Gleason scoring, do not discriminate between stage pT2 and stages pT3/pT4 [1, 2], thus hampering a central tenet for cancer patient stratification [3].